Edgar Filing: REPLIDYNE INC - Form 8-K

REPLIDYNE INC Form 8-K June 06, 2008

executive offices)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 6, 2008 (June 5, 2008)
REPLIDYNE, INC.

(Exact name of registrant as specified in its charter)

Delaware000-5208284-1568247(State or other jurisdiction of incorporation or organization)(Commission File Number)(I.R.S. Employerincorporation or organization)Identification No.)1450 Infinite Drive,80027Louisville, Colorado
(Address of principal(Zip Code)

303-996-5500

(Registrant s telephone number, including area code)

Not Applicable

(Former name, former address and former fiscal year, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.05 Costs Associated with Exit or Disposal Activities

On June 5, 2008, Replidyne, Inc. (the Company) commenced and completed a restructuring of its operations pursuant to which it will incur approximately \$0.7 million of expense representing cash expenditures for employee related severance benefits pertaining to the termination of the employment of 12 employees. Actions by the Company related to this restructuring were completed on June 5, 2008.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

REPLIDYNE, INC.

Dated: June 6, 2008 By: /s/ Mark L. Smith

Mark L. Smith

Chief Financial Officer Principal

Accounting Officer